[1] 钱 雪, 王祖巧, 韩国平, 等. 辅酶Q 的药理与应用[J]. 食品与药品, 2006, 8(01):16-19. [2] 李 全, 古 昆, 程晓红. 辅酶 Q10的合成方法研究进展[J]. 合成化学, 2007, 15(3): 266-269.[3] SALVATOR P, SILVANA F, STEVEN J, et al. Coenzyme Q10 in cardiovascular disease[J]. Mitochondrion, (2007), 7S; S154–S167.[4] HIROSHI K, KENJI F, TAIZO K, et al. Food content of ubiquinol-10 and ubiquinone-10 in the Japanese diet[J]. Journal of Food Composition and Analysis, 2008, 21: 199–210.[5] JOHN N, HATHCO N, ANDREW S. Risk assessment for coenzyme Q10 (Ubiquinone) [J]. Regulatory Toxicology and Pharmacology, 2006, 45: 282–288.[6] BEN-MEIR A, CHONG J, BORREGO-ALVAREZ A, et al. CoQ10 treatment can improve fertility and oocyte quality in old mice[J]. Fertility and Sterility, 2001, 96: S106 [7] EVANS M, BAISLEY J, BARSS S, et al. A randomized, double-blind trial on the bioavailability of two CoQ10 formulations[J]. Journal of Functional Foods, 2009, 1: 65-73.[8] JAE-SHIN K, JUN-SEOB K. Assembly of Coenzyme Q10 nanostructure resembling nascent discoidal high density lipoprotein particle[J]. Biochemical and Biophysical Research Communications, 2009, 388: 217–221.[9] YANG Yue, ZhouHuafeng, LiuGuanlan, et al. The advantages of a novel CoQ10 delivery system in skin photo-protection[J]. International Journal of Pharmaceutics, 2010, 392: 57–63.[10] KOMMURU T.R., GURLEY B, KHAN M.A., et al. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment[J]. International Journal of Pharmaceutics, 2001, 212: 233–246.[11] TERAO K, DAISUKE N, HIROSHI F, et al Enhancement of oral bioavailability of coenzyme Q10 by complexation with c-cyclodextrin in healthy adults[J]. Nutrition Research, 2006, 26: 503– 508.[12] MIRKO P, BUTINAR B, LUKANC B, et al Bioavailability of water-soluble CoQ10 in beagle dogs[J]. Journal of Pharmaceutical and Biomedical Analysis, 2008, 47: 918–922.[13] 谢玉洁, 王洁欣, 乐 园, 等. 反溶剂重结晶法制备阿奇霉素超细粉体[J]. 北京化工大学学报, 2011,38(3): 17-21.[14] Hai-Xia Zhanga, Jie-XinWanga, Zhi-Bing Zhang, et al. Micronization of atorvastatin calcium by antisolvent precipitation process [J]. International Journal of Pharmaceutics, 2009, 374: 106–113.[15] SAMEER V, DALVI H, DAVE R N. Dave. Analysis of nucleation kinetics of poorly water-soluble drugs in presence of ultrasound and hydroxypropyl methyl cellulose during antisolvent precipitation[J]. International Journal of Pharmaceutics , 2010, 387: 172–179.[16] ZIMMEMANN A, ELEMA M R, HANSEN T, et al. Determination of surface-adsorbed excipients of various types on drug particles prepared by antisolvent precipitation using HPLC with evaporative light scattering detection[J]. Journal of Pharmaceutical and Biomedical Analysis, 2007, 44: 874–880.[17] 任夫健, 张同来, 于 伟. 药物微粉制备及防团聚技术[J]. 现代化工, 2005,25(10): 66-68.[18] 韩 冰, 刘学武, 张晓冬, 等. 超临界反溶剂过程在生物制药中的应用[J]. 药学进展 , 2003, 27(1): 26-29. [19] 刘学武, 李志义, 韩 冰, 等. 超临界反溶剂法制备超细微粒[J]. 现代化工, 2003, 23(1): 242-244.[20] TAVARES CARDOSOA M.A., GERALDES V, CABRA J.M.S, et al. Characterization of minocycline powder micronized by a supercritical antisolvent (SAS) process[J]. J. of Supercritical Fluids , 2008, 46; 71–76.[21] DONGA Y, WAI.KIONG Ng, SHEN S, et al. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation[J]. International Journal of Pharmaceutics , 2009, 375; 84–88.[22] 季 华, 乐 园, 沈志刚, 等. 反溶剂重结晶法制备多晶型比卡鲁胺[J]. 北京化工大学学报, 2008, 35(4): 14-17.[23] 宋湘玲, 王洁欣, 陈建峰, 等. 反溶剂重结晶法制备萘普生超细微粒[J]. 化学反应工程与工艺2007, 23(3):212-215.[24] 徐 溢, 唐守渊, 张晓凤. 金属表面硅烷试剂膜结构及性能表征方法[J]. 光谱学与光谱分析, 2004,24(4): 495-498.[25] Zhang Haixia, WangJiexin, Zhang Zhibing, et al. Micronization of atorvastatin calcium by antisolvent precipitation process[J]. International Journal of Pharmaceutics , 2009, 374:106–113.[26] POZARNSKY G, MATIJEVIC E. Preparation of monodisperse colloids of biologically active compounds1. Naproxen, Colloids and Surfaces A [J]. Physicochemical and Engineering Aspects, 1997, (125): 47-52.[27] MATTEUCCI M.E, HOTZE M.A, JOHNSTON K.P, et al. Drug nanoparticles by antisolvent precipitation: Mixing energy versus surfactant stabilization[J]. Langmuir, 2006, 22(21 ): 8951-8959.[28] VIOLANTO M.R, FISHCHER H.W. Method for making uniformly sized particles from water-insoluble organic compounds [P]. US Patent.:4826689, 1989.[29] 吴会军, 向兰, 金永成, 等. 高分散氢氧化镁粉体的制备及其影响因素[J]. 无机材料学报, 2004, 19(2):1181–1185.[30] 安崇伟. 重结晶过程中HMX晶形影响因素与球形化工艺研究[D]. 中北大学, 2005: 34–35.[31] 张克从, 张乐潓. 晶体生长科学与技术[M]. 北京:科学出版社, 1997: 57–60. |